Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C

Antiviral Research

Volumn 67, Issue 1, 2005, Pages 46-54

  Furusyo, Norihiro ^a,b   Kubo, Norihiko ^b   Toyoda, Kazuhiro ^b   Takeoka, Hiroaki ^b   Nabeshima, Shigeki ^a   Murata, Masayuki ^a   Nakamuta, Makoto ^c   Hayashi, Jun ^a,b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus (HCV); Interferon (IFN ); Interferon (IFN ); Interleukin 4 (Il 4); Ribavirin (RIB)

Indexed keywords

CYTOKINE; INTERLEUKIN 4; IONOMYCIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENOTYPE; HELPER CELL; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 20444424931     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2005.04.001     Document Type: Article

References (37)

1. Q.L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, and M. Houghton Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359 362
2. S. Crotty, D. Maag, J.J. Arnold, W. Zhong, J.Y. Lau, Z. Hong, R. Andino, and C.E. Cameron The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen Nat. Med. 6 2000 1375 1379
3. A.M. Di Bisceglie, P. Martin, C. Kassianides, M. Lisker-Melman, L. Murray, J. Waggoner, Z. Goodman, S.M. Banks, and J.H. Hoofnagle Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial N. Engl. J. Med. 321 1989 1506 1510
4. A.M. Di Bisceglie, M. Shindo, T.L. Fong, M.W. Fried, M.G. Swain, N.V. Bergasa, C.A. Axiotis, J.G. Waggoner, Y. Park, and J.H. Hoofnagle A pilot study of ribavirin therapy for chronic hepatitis C Hepatology 16 1992 649 654
5. A.M. Di Bisceglie, H.S. Conjeevaram, M.W. Fried, R. Sallie, Y. Park, C. Yurdaydin, M. Swain, D.E. Kleiner, K. Mahaney, and J.H. Hoofnagle Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo controlled trail Ann. Intern. Med. 123 1995 897 903
6. H.M. Diepolder, R. Zachoval, R.M. Hoffmann, E.A. Wierenga, T. Santantonio, M.C. Jung, D. Eichenlaub, and G.R. Pape Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection Lancet 346 1995 1006 1007
7. A. Doglio, C. Laffont, F.X. Caroli-Bosc, P. Rochet, and J. Lefebvre Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant J. Clin. Microbiol. 37 1999 1567 1569
8. H.B. El-Serag, and A.C. Mason Rising incidence of hepatocellular carcinoma in the United States N. Engl. J. Med. 340 1999 745 750
9. N. Furusyo, J. Hayashi, K. Ueno, Y. Sawayama, Y. Kawakami, Y. Kishihara, and S. Kashiwagi Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis Clin. Ther. 19 1997 1352 1367
10. N. Furusyo, J. Hayashi, M. Ohmiya, Y. Sawayama, Y. Kawakami, I. Ariyama, N. Kinukawa, and S. Kashiwagi Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection Dig. Dis. Sci. 44 1999 608 617
11. N. Furusyo, J. Hayashi, K. Kashiwagi, H. Nakashima, S. Nabeshima, Y. Sawayama, N. Kinukawa, and S. Kashiwagi Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia Dig. Dis. Sci. 47 2002 535 542
12. J. Hayashi, Y. Kishihara, K. Yamaji, E. Yoshimura, M. Ohmiya, Y. Tani, H. Ikematsu, and S. Kashiwagi Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus Dig. Dis. Sci. 40 1995 1837 1841
13. J. Hayashi, Y. Kishihara, K. Yamaji, N. Furusyo, T. Yamamoto, Y. Pae, Y. Etoh, H. Ikematsu, and S. Kashiwagi Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection Hepatology 25 1997 697 701
14. J. Hayashi, Y. Kishihara, K. Ueno, K. Yamaji, Y. Kawakami, N. Furusyo, Y. Sawayama, and S. Kashiwagi Age-related response to interferon alfa treatment in women vs. men with chronic hepatitis C virus infection Arch. Intern. Med. 158 1998 177 181
15. J. Hayashi, N. Furusyo, I. Ariyama, Y. Sawayama, Y. Etoh, and S. Kashiwagi A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia J. Infect. Dis. 181 2000 1523 1527
16. S. Kakumu, K. Yoshioka, T. Wakita, T. Ishikawa, M. Takayanagi, and Y. Higashi A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C Gastroenterology 105 1993 507 512
17. Y. Kawakami, S. Nabeshima, N. Furusyo, Y. Sawayama, J. Hayashi, and S. Kashiwagi Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection Am. J. Gastroenterol. 95 2000 227 232
18. S. Khakoo, P. Glue, L. Grellier, B. Wells, A. Bell, C. Dash, I. Murray-Lyon, D. Lypnyj, B. Flannery, K. Walters, and G.M. Dusheiko Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions Br. J. Clin. Pharmacol. 46 1998 563 570
19. S. Lee, G.C. Macquillan, N.M. Keane, J. Flexman, G.P. Jeffrey, M.A. French, J. Brochier, and P. Price Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alfa and ribavirin Immunol. Cell. Biol. 80 2002 391 397
20. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, Z.D. Goodman, K. Koury, M. Ling, and J.K. Albrecht Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
21. N. Masaki, S. Fukushima, and S. Hayashi Lower Th-1/Th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C Dig. Dis. Sci. 47 2002 2163 2169
22. G. Missale, R. Bertoni, V. Lamonaca, A. Valli, M. Massari, C. Mori, M.G. Rumi, M. Houghton, F. Fiaccadori, and C. Ferrari Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response J. Clin. Invest. 98 1996 706 714
23. G. Missale, E. Cariani, V. Lamonaca, A. Ravaggi, A. Rossini, R. Bertoni, M. Houghton, Y. Matsuura, T. Miyamura, F. Fiaccadori, and C. Ferrari Effects of interferon treatment on the antiviral T cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients Hepatology 26 1997 792 797
24. T.R. Mosmann, and S. Sad The expanding universe of T cell subsets: Th1, Th2 and more Immunology. Today 17 1996 138 146
25. M. Murata, S. Nabeshima, N. Maeda, H. Nakashima, S. Kashiwagi, and J. Hayashi Increased frequency of IFN-gamma-producing peripheral CD8+ T cells with memory-phenotype in patients with chronic hepatitis C J. Med. Virol. 67 2002 162 170
26. Q. Ning, D. Brown, J. Parodo, M. Cattral, R. Gorczynski, E. Cole, L. Fung, J.W. Ding, M.F. Liu, O. Rotstein, M.J. Phillips, and G. Levy Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response J. Immunol. 160 1998 3487 3493
27. H. Okamoto, Y. Sugiyama, S. Okada, K. Kurai, Y. Akahane, Y. Sugai, T. Tanaka, K. Sato, F. Tsuda, Y. Miyakawa, and Y. Mayumi Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources J. Gen. Virol. 73 1992 673 679
28. J.L. Patterson, and R. Fernandez-Larsson Molecular mechanisms of action of ribavirin Rev. Infect. Dis. 12 1990 1139 1146
29. M. Peters Actions of cytokines on the immune response and viral interactions: an overview Hepatology 23 1996 909 916
30. G. Piazzolla, C. Tortorella, G. Fiore, M. Fanelli, A. Pisconti, and S. Antonaci Interleukin-12 p40/p70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C J. Interferon Cytokine. Res. 21 2001 453 461
31. O. Reichard, J. Andersson, R. Schvarcz, and O. Weiland Ribavirin treatment for chronic hepatitis C Lancet 337 1991 1058 1061
32. R. Schvarcz, Z.B. Yun, A. Sonnerborg, and O. Weiland Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone J. Med. Virol. 46 1995 43 47
33. R.W. Sidwell, J.H. Huffman, G.P. Khare, L.B. Allen, J.T. Witkowski, and R.K. Robins Broad-spectrum antiviral activity of Virazole: 1-beta-d- ribofuranosyl-1,2,4-triazole-3-carboxamide Science 177 1972 705 706
34. P. Simmonds, A. Alberti, H.J. Alter, F. Bonino, D.W. Bradley, C. Brechot, J.T. Brouwer, S.W. Chan, K. Chayama, D.S. Chen, Q.L. Choo, M. Colombo, Cuypers HTM, T. Date, G.M. Dusheiko, J.I. Esteban, O. Fay, S.J. Hadzyannis, J. Han, A. Hatzakis, E.C. Holmes, H. Hotta, M. Houghton, B. Irwine, M. Kohara, J.A. Kolberg, G. Kuo, Lau JYN, P.N. Lelie, G. Maertens, F. McOmish, and G.W. Snedecar A proposed system for the nomenclature of hepatitis C virus genotypes Hepatology 19 1994 1321 1324
35. R.C. Tam, B. Pai, J. Bard, C. Lim, D.R. Averett, U.T. Phan, and T. Milovanovic Ribavirin polarizes human T cell responses toward a Type 1 cytokine profile J. Hepatol. 30 1999 373 382
36. S.D. Taylor-Robinson, G.R. Foster, S. Arora, S. Hargreaves, and H.C. Thomas Increase in primary liver cancer in the UK, 1979-1994 Lancet 350 1997 1142 1143
37. K. Yamaji, J. Hayashi, Y. Kawakami, N. Furusyo, Y. Sawayama, Y. Kishihara, Y. Etoh, and S. Kashiwagi Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response J. Clin. Gastroenterol. 26 1998 193 199